Pemphigus vulgaris (PV) belongs to the group of autoimmune blistering diseases. PV can affect not ABSTRACT only mucous membranes, but also the skin and it is characterized by serum IgG autoantibodies against desmoglein 1 and 3, two major components of desmosomes. The introduction of glucocorticoids improved dramatically the prognosis of patients affected by PV. However, long-term use of high dose corticosteroids and adjuvant steroid-sparing immunosuppressants can lead to several adverse events. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been recently approved as in-label therapy for PV, leading to an improvement of the prognosis and higher remission rate. Furthermore, other anti B-cell therapies and several anti-CD20 biosimilars have been introduced in the clinical practice. We focused on present and future therapeutic approaches in PV.

Pemphigus Vulgaris: Present and Future Therapeutic Strategies / Didona, D.; Paolino, G.; Di Zenzo, G.; Didona, B.; Pampena, R.; Di Nicola, M. R.; Mercuri, S. R.. - In: DERMATOLOGY PRACTICAL & CONCEPTUAL. - ISSN 2160-9381. - 12:1(2022). [10.5826/dpc.1201a37]

Pemphigus Vulgaris: Present and Future Therapeutic Strategies

Paolino G.
Secondo
;
Mercuri S. R.
Ultimo
2022-01-01

Abstract

Pemphigus vulgaris (PV) belongs to the group of autoimmune blistering diseases. PV can affect not ABSTRACT only mucous membranes, but also the skin and it is characterized by serum IgG autoantibodies against desmoglein 1 and 3, two major components of desmosomes. The introduction of glucocorticoids improved dramatically the prognosis of patients affected by PV. However, long-term use of high dose corticosteroids and adjuvant steroid-sparing immunosuppressants can lead to several adverse events. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been recently approved as in-label therapy for PV, leading to an improvement of the prognosis and higher remission rate. Furthermore, other anti B-cell therapies and several anti-CD20 biosimilars have been introduced in the clinical practice. We focused on present and future therapeutic approaches in PV.
2022
Anti-CD20 antibodies
Neonatal Fc receptor (FcRn)
Pemphigus
Rituximab
Treatment
File in questo prodotto:
File Dimensione Formato  
dp1201a37.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 618.45 kB
Formato Adobe PDF
618.45 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/150937
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact